Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. Retz M, et al. Among authors: beeker a. Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529901 Clinical Trial.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: beeker a. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
De Jonge AV, Bruins WSC, Duetz C, Korst CLBM, Rentenaar R, Cosovic M, Eken M, Kersten MJ, Sandberg Y, Van Rijn RS, Fijnheer R, Mutsaers P, Vergote VKJ, Issa D, Beeker A, Bilgin YM, Visser O, Van Werkhoven E, Roemer MGM, Chamuleau MED, Mutis T. De Jonge AV, et al. Among authors: beeker a. Haematologica. 2024 Nov 1;109(11):3760-3765. doi: 10.3324/haematol.2024.285170. Haematologica. 2024. PMID: 38961740 Free PMC article. No abstract available.
Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, van Maanen T, Lindauer-van der Werf G, Beeker A, Timmers GJ, Schaar CG, Soesan M, Poddighe PJ, de Jong D, Chamuleau ME. de Jonge AV, et al. Among authors: beeker a. Eur J Cancer. 2016 Mar;55:140-6. doi: 10.1016/j.ejca.2015.12.001. Epub 2016 Jan 25. Eur J Cancer. 2016. PMID: 26820684 Review.
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A. Meulendijks D, et al. Among authors: beeker a. Cancer. 2016 May 1;122(9):1434-43. doi: 10.1002/cncr.29864. Epub 2016 Mar 11. Cancer. 2016. PMID: 26970343 Free article. Clinical Trial.
Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije AJ, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS). Nieuweboer AJ, et al. Among authors: beeker a. Clin Cancer Res. 2017 Apr 1;23(7):1679-1683. doi: 10.1158/1078-0432.CCR-16-2110. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702823 Clinical Trial.
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Bouman-Wammes EW, van den Berg HP, de Munck L, Beeker A, Smorenburg CH, Vervenne WL, Coenen JLLM, Verheul HMW, Gerritsen WR, Van den Eertwegh AJM. Bouman-Wammes EW, et al. Among authors: beeker a. Eur J Cancer. 2018 Feb;90:1-9. doi: 10.1016/j.ejca.2017.11.021. Epub 2017 Dec 18. Eur J Cancer. 2018. PMID: 29268139 Clinical Trial.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
72 results